Trial Profile
A retrospective study of efficacy and safety of ivosidenib locally advanced or metastatic intrahepatic cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2022 New trial record
- 17 Sep 2022 Results published in the Targeted Oncology